AHA Comments to FDA Re: Market Claims in Direct-to-Consumer Prescription Drug Print Ads

AHA comments on the FDA study on market claims in direct-to-consumer prescription drug print advertising.

Key Resources

Related Resources

Advisory
AHA and Health-ISAC Joint Threat Bulletin: Actionable Indicators of Compromise Related to Recent Health Care Ransomware Attacks
Member
Letter/Comment
AHA Comments on FTC Anticompetitive Deregulations RFI
Public
Letter/Comment
AHA Comments on DOJ Anticompetitive Deregulations RFI
Public
Advisory
AHA Summary of One Big Beautiful Bill Act’s Provisions Impacting Hospitals and Health Systems
Member Non-Fed
Special Bulletin
House Passes Reconciliation Bill with Significant Policy Changes and Reductions to Medicaid, Other Health Care Programs
Member Non-Fed
Letter/Comment
AHA Senate Letter Supporting Improving Seniors’ Timely Access to Care Act
Public